ANTI-TUMOR COMPOUNDS

摘要

The invention is in particular related to compounds with the general formula A-B, which in the vicinity of tumor cells result in a positively charged moiety B and an uncharged or negatively charged moiety A, whereby said moiety B is able to induce blood clotting by interacting with negatively charged heparin-like substances lining vascular endothelia and whereby the positive charge is reversibly masked by the uncharged or negatively charged moiety A in order to prevent unspecific disseminated blood coagulation and toxicity. The polycation moiety B is able to induce blood clotting by interacting with negatively charged heparin-like substances lining vascular endothelia. The positive charges of the B moiety within the prodrug are masked by the uncharged or negatively charged moiety A in order to prevent unspecific disseminated blood coagulation and toxicity. B is either a covalent assembly of positively charged chemical groups or a positively charged molecule, which in aqueous solutions forms non-covalent polycations due to its propensity to form intermolecular aggregates. The present invention also relates to the pharmaceutical composition comprising the compound and a pharmaceutically acceptable adjuvant or excipient. The present invention relates to a compound for use in medicine, in particular in the use of this compound for the manufacture of a medicament and its use for the treatment of a subject.